Pharmacokinetics of linezolid in critically ill patients

References

• Welshman IR, Sisson TA, Jungbluth GL, et al. Linezolidabsolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos. 2001;22(3):91–97.
   PubMed Web of Science ®Google Scholar
• Islinger F, Dehghanyar P, Sauermann R, et al. The effect of food on plasma and tissue concentrations of linezolid aftermultiple doses. Int J Antimicrob Agents. 2006;27(2):108–112.
   PubMed Web of Science ®Google Scholar
• Helmy SA. Pharmacokinetics and relative bioavailability evaluation oflinezolid suspension and tablet formulations. Drug Res (Stuttg). 2013;63(9):489–494.
   PubMedGoogle Scholar
• Stalker DJ, Jungbluth GL, Hopkins NK, et al. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinoneantibiotic, in healthy volunteers. J Antimicrob Chemother. 2003;51(5):1239–1246.
   PubMed Web of Science ®Google Scholar
• Wiskirchen DE, Shepard A, Kuti JL, et al. Determination of tissue penetration and pharmacokinetics of linezolid in patients with diabetic foot infections using in vivo microdialysis. Antimicrob Agents Chemother. 2011;55(9):4170–4175.
   PubMed Web of Science ®Google Scholar
• George JM, Fiscella R, Blair M, et al. Aqueous and vitreous penetration of linezolid and levofloxacin afteroral administration. J Ocul Pharmacol Ther. 2010;26(6):579–586.
   PubMed Web of Science ®Google Scholar
• Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23(4):858–883.
   PubMed Web of Science ®Google Scholar
• Fiscella RG, Lai WW, Buerk B, et al. Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration. Ophthalmology. 2004;111(6):1191–1195.
   PubMed Web of Science ®Google Scholar
• Dehghanyar P, Bürger C, Zeitlinger M, et al. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother. 2005;49(6):2367–2371.
   PubMed Web of Science ®Google Scholar
• Slatter JG, Stalker DJ, Feenstra KL, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C] linezolid to healthy human subjects. Drug Metab Dispos. 2001;29(8):1136–1145.
   PubMed Web of Science ®Google Scholar
• Rana B, Butcher I, Grigoris P, et al. Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother. 2002;50(5):747–750.
   PubMed Web of Science ®Google Scholar
• MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother. 2003;51(Suppl 2):ii17–ii25.
   PubMedGoogle Scholar
• Frost P, Wise MP. Recognition and early management of the critically ill ward patient. Br J Hosp Med (Lond). 2007;68(10):M180–M183.
   PubMed Web of Science ®Google Scholar
• Carson SS. Definitions and epidemiology of the chronically critically ill. Respir Care. 2012;57(6):848–856. discussion 856-8
   PubMed Web of Science ®Google Scholar
• Scaglione F. Can we transfer pharmacokinetics/pharmacodynamics ofantimicrobials into clinical practice? Int J Antimicrob Agents. 2015;46(Suppl 1):S40–S42.
   PubMed Web of Science ®Google Scholar
• Blot S, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient - concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3–11.
   PubMed Web of Science ®Google Scholar
• Linezolid. Tuberculosis (Edinb). 2008;88(2):122–125.
   PubMedGoogle Scholar
• Felton T, Hope W, Roberts J. Clinical studies: how severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it? Diagn Microbiol Infect Dis. 2014;79:441–447.
   PubMed Web of Science ®Google Scholar
• PubMed. US National Library of Medicine National Institutes of Health, search. 1996. [cited 2016 Jan 31]. Available from: http://www.ncbi.nlm.nih.gov/pubmed.
   Google Scholar
• EBSCO discovery (discovery service for KoBSON - Serbia), search. 2010. [cited 2016 Jan 31]. Available from: http://eds.b.ebscohost.com.proxy.kobson.nb.rs.
   Google Scholar
• Serbian citation index (SCIndex), centre for evaluation in education and science, search. 2001. [cited 2016 Jan 31]. Available from: http://scindeks.ceon.rs/?lang=en.
   Google Scholar
• El-Assal MI, Helmy SA. Single-dose linezolid pharmacokinetics in critically ill patients with impaired renal function especially chronic hemodialysis patients. Biopharm Drug Dispos. 2014;35(7):405–416.
   PubMed Web of Science ®Google Scholar
• Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. 2011;66(Suppl 4):iv7–iv15.
   PubMed Web of Science ®Google Scholar
• Swoboda S, Ober MC, Lichtenstern C, et al. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol. 2010;66(3):291–298.
   PubMed Web of Science ®Google Scholar
• Luque S, Grau S, Alvarez-Lerma F, et al. Plasma and cerebrospinal fluid concentrations oflinezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections. Int J Antimicrob Agents. 2014;44(5):409–415.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Baguneid M, Bouza E, et al. European perspective and update on the management of complicated skin and soft tissuei nfections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect. 2014;20(Suppl 4):3–18.
   PubMed Web of Science ®Google Scholar
• Buerger C, Plock N, Dehghanyar P, et al. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother. 2006;50(7):2455–2463.
   PubMed Web of Science ®Google Scholar
• Thallinger C, Buerger C, Plock N, et al. Effect of severity of sepsis on tissue concentrations oflinezolid. J Antimicrob Chemother. 2008;61(1):173–176.
   PubMed Web of Science ®Google Scholar
• Boselli E, Breilh D, Caillault-Sergent A, et al. Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia. J Antimicrob Chemother. 2012;67(5):1207–1210.
   PubMed Web of Science ®Google Scholar
• De Pascale G, Fortuna S, Tumbarello M, et al. Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs. continuous administration. Intensive Care Med. 2015;41(1):103–110.
   PubMed Web of Science ®Google Scholar
• Adembri C, Fallani S, Cassetta MI, et al. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents. 2008;31(2):122–129.
   PubMed Web of Science ®Google Scholar
• Yagi T, Naito T, Doi M, et al. Plasma exposure of free linezolid and its ratio to minimum inhibitory concentration varies in critically ill patients. Int J Antimicrob Agents. 2013;42(4):329–334.
   PubMed Web of Science ®Google Scholar
• Dong H, Wang X, Dong Y, et al. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients. Int J Antimicrob Agents. 2011;38(4):296–300.
   PubMed Web of Science ®Google Scholar
• Mimoz O, Montravers P, Paiva JA. Continuous administration of linezolid in pneumonia: what is the level of proof? Intensive Care Med. 2015;41(1):157–159.
   PubMed Web of Science ®Google Scholar
• Zoller M, Maier B, Hornuss C, et al. Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. Crit Care. 2014;18(4):R148.
   PubMed Web of Science ®Google Scholar
• Plock N, Buerger C, Joukhadar C, et al. Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients. Drug Metab Dispos. 2007;35(10):1816–1823.
   PubMed Web of Science ®Google Scholar
• Hoyo I, Martínez-Pastor J, Garcia-Ramiro S, et al. Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections. Scand J Infect Dis. 2012;44(7):548–550.
   PubMed Web of Science ®Google Scholar
• Fung HB, Kirschenbaum HL, Ojofeitimi BO. Linezolid: an oxazolidinone antimicrobial agent. Clin Ther. 2001;23(3):356–391.
   PubMed Web of Science ®Google Scholar
• Tsai D, Jamal JA, Davis JS, et al. Interethnic differences in pharmacokinetics of antibacterials. Clin Pharmacokinet. 2015;54(3):243–260.
   PubMed Web of Science ®Google Scholar
• Zhang YM, Yu W, Zhou N, et al. High frequency of thrombocytopenia in patients with acute-on-chronic liver failure treated with linezolid. Hepatobiliary Pancreat Dis Int. 2015;14(3):287–292.
   PubMed Web of Science ®Google Scholar
• Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003;47(9):2775–2780.
   PubMed Web of Science ®Google Scholar
• Fiaccadori E, Maggiore U, Rotelli C, et al. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, orcontinuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med. 2004;32(12):2437–2442.
   PubMed Web of Science ®Google Scholar
• Meyer B, Kornek GV, Nikfardjam M, et al. Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration. J Antimicrob Chemother. 2005;56(1):172–179.
   PubMed Web of Science ®Google Scholar
• Mauro LS, Peloquin CA, Schmude K, et al. Clearance of linezolidvia continuous venovenous hemodiafiltration. Am J Kidney Dis. 2006;47(6):e83–e86.
   PubMed Web of Science ®Google Scholar
• Ashley C, Dunleavy A. The renal drug handbook. 4th ed. London: Radcliffe Publishing; 2014.
   Google Scholar
• Cremaschi E, Maggiore U, Maccari C, et al. Linezolid levels in a patient with biliary tract sepsis, severe hepatic failure and acute kidney injury on sustained low-efficiency dialysis (SLED). Minerva Anestesiol. 2010;76(11):961–964.
   PubMed Web of Science ®Google Scholar
• Sisson TL, Jungbluth GL, Hopkins NK. Age and sex effects on the pharmacokinetics of linezolid. Eur J Clin Pharmacol. 2002;57(11):793–797.
   PubMed Web of Science ®Google Scholar